Molecular Partners Ag (MOLN) Current Assets (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Current Assets of $105899.4 for Q1 2026, down 30.48% year-on-year from $152326.0 in Q1 2025, and down 12.63% on a QoQ basis from $121208.3 in Q4 2025.
Molecular Partners Ag (MOLN) Current Assets (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Current Assets for 7 consecutive years, with $105899.4 the latest figure, recorded in Q1 2026.
- Quarterly Current Assets fell 30.48% year-over-year to $105899.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105899.4 (down 30.48% YoY) and the FY2025 annual result came in at $121208.3, down 99.93% from the prior year.
- Current Assets slipped to $105899.4 in Q1 2026 per MOLN's latest filing, from $121208.3 in the prior quarter.
- Over the last five years, Current Assets for MOLN reached as high as $302.6 million in Q2 2022 and fell as low as $105899.4 in Q1 2026.
- A 5-year average of $82.0 million and a median of $256753.4 in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets surged 55.2% — and 2025, when it sank 99.93%.
- Year by year, Current Assets stood at $264.4 million in 2022, then retreated by 17.95% to $217.0 million in 2023, then declined by 18.83% to $176.1 million in 2024, then plunged by 99.93% to $121208.3 in 2025, then dropped by 12.63% to $105899.4 in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $105899.4, $121208.3, and $136211.9 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 289.93 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 73.04 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 6.60 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 35.73 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 11.73 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 18.21 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 521.86 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 8.07 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.97 Bn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | 105,899.44 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 105,899.44 |
| Dec 31, 2025 | 121,208.32 |
| Sep 30, 2025 | 136,211.93 |
| Jun 30, 2025 | 145,631.70 |
| Mar 31, 2025 | 152,326.05 |
| Dec 31, 2024 | 176.12 Mn |
| Sep 30, 2024 | 172,589.76 |
| Jun 30, 2024 | 183.12 Mn |
| Mar 31, 2024 | 206,435.91 |
| Dec 31, 2023 | 216.97 Mn |
| Sep 30, 2023 | 239,940.49 |
| Jun 30, 2023 | 248.97 Mn |
| Mar 31, 2023 | 256,753.41 |
| Dec 31, 2022 | 264.44 Mn |
| Sep 30, 2022 | 283,392.06 |
| Jun 30, 2022 | 302.65 Mn |
| Mar 31, 2022 | 328,749.29 |
| Dec 31, 2021 | 178.07 Mn |
| Sep 30, 2021 | 182,593.58 |
| Dec 31, 2020 | 196.69 Mn |